The cytotoxic drugs market size is expected to grow significantly during the forecast timeframe, owing to increasing incidences of cancer worldwide. According to World Health Organization’s (WHO) 2018 report, around 9.6 million deaths were recorded due to cancer and around 18.1 million new cases of cancer were diagnosed in 2018 worldwide.

Furthermore, increasing number of cytotoxic drug approvals is expected to boost the market growth. For instance, in November 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option. Other potential factor that contributes to cytotoxic drugs market revenue growth is increasing therapeutic area of cytotoxic drugs in auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection because of its immunosuppressive or anti–proliferative effects.

Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2533

The major restraining factor for the cytotoxic drugs market growth is adverse side effects shown by consumption of cytotoxic drugs such as nausea and vomiting, severe diarrhea, and damage to bone marrow. Cytotoxic drugs can be toxic to other organ systems and lead to conditions such as gastrointestinal toxicity, neurotoxicity renal toxicity, and cardiovascular toxicity. For instance, according to NHS Lothian Joint Formulary, drugs such as fluorouracil, doxorubicin, and oral capecitabine may cause severe stomatitis, diarrhea, and coronary spasm mimicking angina. Moreover, systemic anti-cancer therapy (SACT) drugs increase the risk of thromboembolic disease eventually restraining the cytotoxic drugs market growth.

North America is expected to hold a dominant position in the cytotoxic drugs market over the forecast period, owing to increasing awareness and availability of wide range of cytotoxic drugs in the region. According to a study published in National Center for Biotechnology Information (NCBI) in 2017, the U.S. Food and Drug Administration has approved 61 cytotoxic drugs for cancer, which help in increasing the survival rates of cancer patients.

Asia Pacific cytotoxic drugs market size is expected to witness significant growth, owing to large patient base and increasing healthcare insurance schemes in the region. For instance, in 2018, the Government of India launched Pradhan Mantri Jan Arogya Yojana (PMJAY) to provide health insurance worth US$ 7,124.54 to over 100 million families, annually.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2533

Key players operating in the global cytotoxic drugs market include, Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, Pfizer Inc., Celgene Corporation, Amgen Inc., Novartis AG Merck and Co., Johnson and Johnson, and GlaxoSmithKline Plc.